Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 5, 2020

Primary Completion Date

March 5, 2021

Study Completion Date

March 5, 2021

Conditions
Corona Virus InfectionSARS-CoV 2SARS PneumoniaPneumonia
Interventions
DRUG

High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma

Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.

Trial Locations (2)

22903

University of Virginia Medical Center, Charlottesville

University of Virginia, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER

NCT04374565 - Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia | Biotech Hunter | Biotech Hunter